Mydecine Innovations Group Stock Last Dividend Paid
| MYCOF Stock | USD 0 0 33.33% |
Mydecine Innovations Group fundamentals help investors to digest information that contributes to Mydecine Innovations' financial success or failures. It also enables traders to predict the movement of Mydecine Pink Sheet. The fundamental analysis module provides a way to measure Mydecine Innovations' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mydecine Innovations pink sheet.
Mydecine |
Mydecine Innovations Group Company Last Dividend Paid Analysis
Mydecine Innovations' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, Mydecine Innovations Group has a Last Dividend Paid of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Earnings Calls Now
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges |
| All Next | Launch Module |
Mydecine Fundamentals
| Return On Equity | -12.24 | |||
| Return On Asset | -1.76 | |||
| Current Valuation | 8.64 M | |||
| Shares Outstanding | 13.01 M | |||
| Shares Owned By Insiders | 8.71 % | |||
| Price To Book | 23.41 X | |||
| Price To Sales | 677.59 X | |||
| Revenue | 7.49 K | |||
| Gross Profit | 7.49 K | |||
| EBITDA | (23.14 M) | |||
| Net Income | (28.9 M) | |||
| Cash And Equivalents | 324.15 K | |||
| Cash Per Share | 0.04 X | |||
| Total Debt | 4.35 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 1.26 X | |||
| Book Value Per Share | (0.36) X | |||
| Cash Flow From Operations | (24.05 M) | |||
| Earnings Per Share | (4.68) X | |||
| Target Price | 140.0 | |||
| Number Of Employees | 11 | |||
| Beta | 3.42 | |||
| Market Capitalization | 5.94 M | |||
| Total Asset | 7.58 M | |||
| Z Score | -9.3 | |||
| Net Asset | 7.58 M |
About Mydecine Innovations Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mydecine Innovations Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mydecine Innovations using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mydecine Innovations Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Mydecine Pink Sheet
Mydecine Innovations financial ratios help investors to determine whether Mydecine Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mydecine with respect to the benefits of owning Mydecine Innovations security.